A phase I/II trial of next generation formulation of PAN 90806 in patients with neovacular age-related macular degeneration
Phase of Trial: Phase I/II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs PAN 90806 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- 06 Oct 2017 According to a PanOptica media release, this trial is expected to initiated in early 2018.
- 06 Oct 2017 Planned initiation date changed from 1 Jan 2017 to 1 Jan 2018, according to a PanOptica media release.
- 28 Oct 2016 New trial record